Acetyl-L-carnitine is the carnitine in red meat with an acetyl group added — the change that lets it cross into the brain, which plain L-carnitine can't do at oral doses. That's why the mood and memory evidence is for the acetyl form specifically and doesn't transfer to the L-carnitine sitting next to it on the shelf.
Memory: in mild cognitive impairment and early Alzheimer's, it slows decline on memory and attention tests by a small, consistent margin, showing by three months 1. It's small enough that reviewers split on whether it's worth using 2.
Depression: it matched fluoxetine and amisulpride on mood with far fewer gut, sleep, and sexual side effects, and worked best in older and treatment-resistant patients 3 — the same people whose blood levels of it run low to start 4.
Diabetic nerve pain: a year on 3 g a day cut pain and left more living nerve fibres in a calf biopsy than at the start 5. Gabapentin and duloxetine mute the signal; this touched the nerve itself.
Match the dose to why you're taking it, and give it months.
The felt change is modest and specific. In depression it's the floor coming up: bad mornings less bad, and the side-effect tax of the SSRI easing. In memory it's slope-softening — the crossword you finished last year is one you can still finish. In neuropathy the burning eases from nightly to occasional, and the biopsy shows real nerve underneath. If you weren't in any of the three groups, you take it three months, feel the same, and are out about thirty dollars.
The fine print — when to skip it, and what people get wrong
Skip it during taxane chemo (paclitaxel, docetaxel): given to prevent nerve damage, it made it worse at both six months and a year 6. If your thyroid is underactive and not fully replaced, carnitine blunts thyroid action and can drag you further into it — check labs first 7. With existing heart disease, gut bacteria turn carnitine into TMAO, linked to atherosclerosis; stay low-dose and ask the cardiologist 8.
It's a nootropic: no — nearly every positive cognitive trial enrolled people with mild impairment, never healthy young brains. Carnitine fixes neuropathy, full stop: it helped diabetic nerves and harmed nerves during chemo, so treat it as specific, not a general repair agent. More is better: the dose plateaus, and the long-term heart question grows with duration; most of the upside sits between 1 and 2 g.
- 1Montgomery SA, Thal LJ, Amenta F (2003). Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. International Clinical Psychopharmacology. link
- 2Hudson S, Tabet N (2003). Acetyl-l-carnitine for dementia. Cochrane Database of Systematic Reviews. link
- 3Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S (2018). Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosomatic Medicine. link
- 4Nasca C, Bigio B, Lee FS, Young SP, Kautz MM, Albright A, Beasley J, Millington DS, Mathé AA, Kocsis JH, Murrough JW, McEwen BS, Rasgon N (2018). Acetyl-l-carnitine deficiency in patients with major depressive disorder. Proceedings of the National Academy of Sciences. link
- 5Sima AAF, Calvani M, Mehra M, Amato A (2005). Acetyl-L-Carnitine Improves Pain, Nerve Regeneration, and Vibratory Perception in Patients With Chronic Diabetic Neuropathy: An analysis of two randomized placebo-controlled trials. Diabetes Care. link
- 6Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013). Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. Journal of Clinical Oncology. link
- 7Benvenga S (2008). Effects of L-carnitine on thyroid hormone metabolism and on physical exercise tolerance. Hormone and Metabolic Research. link
- 8Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WHW, Bushman FD, Lusis AJ, Hazen SL (2013). Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine. link
Acetyl-L-Carnitine (ALCAR)
Typical retail pricing ~$10–25/month for 1–2 g/day; ~$120–300/year. Trivial relative to most supplement and medication budgets.
One or two capsules with breakfast and lunch. No lifestyle reorganisation, no timing constraints beyond avoiding late dosing for the small subset who get mild insomnia.
Centenarian RCT (Malaguarnera 2007) showed significant reductions in physical and mental fatigue, with lean-mass gain and fat-mass loss at 2 g/day. Effect concentrated in older, deficient, or fatigued populations; trials in young healthy adults are sparse.
Veronese et al. 2018 meta-analysis (9 RCTs, n=791) found a standardised mean difference of −1.10 on depressive symptom scores vs placebo, with comparable efficacy to fluoxetine and amisulpride and significantly fewer adverse events. Mechanism backed by histone-acetylation work on mGlu2 (Nasca et al. 2018) and a documented plasma ALCAR deficit in MDD patients.
Multiple meta-analyses and RCTs across three clinical populations (MCI/early Alzheimer's, depression, diabetic peripheral neuropathy) at 1.5–3 g/day. Direction of effect replicates; effect sizes are modest outside diabetic neuropathy and depression. Heterogeneity, a Sigma-Tau-funding conflict-of-interest pattern in older trials, the Cochrane skeptical reread, and one clear negative trial in chemo-induced neuropathy (Hershman et al. 2013) keep this off a 4.
Real but modest wellness lift over 4–8 weeks in deficient or fatigued populations: less daily fatigue in elderly trials (Malaguarnera 2007), pain reduction in chronic diabetic neuropathy (Sima et al. 2005). In healthy adults with normal carnitine status, the felt change is small or absent.
Meta-analysis of 21 RCTs in mild cognitive impairment and mild Alzheimer's (Montgomery, Thal & Amenta 2003) shows small but consistent improvement in attention and memory subtests at 1.5–3 g/day over 3–12 months. Cochrane (Hudson & Tabet 2003) calls the effect too modest for routine clinical use. Negligible evidence in cognitively normal users.
No direct mortality evidence; theoretical mitochondrial-support benefit is partially offset by the TMAO–atherosclerosis pathway flagged by Koeth et al. 2013 at chronic high doses. Net contribution likely small and uncertain in either direction.